Phase Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors.

Toshio Kubo,Katsuyuki Hotta,Takashi Ninomiya,Hironari Kato,Shigeru Horiguchi,Atsushi Takamoto,Toshiyuki Kozuki,Naoyuki Nogami,Hiroshi Ishii,Tomohiro Nishina,Daijiro Harada,Shinichi Toyooka,Hiroyuki Okada,Toshiyoshi Fujiwara,Heiichiro Udono,Katsuyuki Kiura

Phase Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors.

2018

Toshio Kubo
Katsuyuki Hotta
Takashi Ninomiya
Hironari Kato
Shigeru Horiguchi
Atsushi Takamoto
Toshiyuki Kozuki
Naoyuki Nogami
Hiroshi Ishii
Tomohiro Nishina
Daijiro Harada
Shinichi Toyooka
Hiroyuki Okada
Toshiyoshi Fujiwara
Heiichiro Udono
Katsuyuki Kiura

TPS3119Background: Although immune-checkpoint inhibitors (ICIs) have shown significant survival benefits in several cancers, optimal outcomes have been limited to subsets of patients. We obtained c...

Keywords:

Nivolumab
Physical therapy
Metformin
Cancer research
Medicine
Oncology
Refractory
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations